AUA 2017: Prevalence of Hormonal Abnormalities in Young Men with Erectile Dysfunction
This was a retrospective single center study of men aged 18-40 years who presented with the complaint of ED and had a hormonal evaluation from 2002- 2016 at a tertiary care institution. Data on demographics, co-morbidities, medications, and hormonal evaluations was obtained for all patients. Hypogonadism was defined as a testosterone level <200 ng/dL and hyperprolactinemia as a prolactin level >13.1 ng/mL.
A total of 2,292 relevant men were identified. The median age was 32.7 years with a larger proportion complaining of ED as they neared age 40 compared to younger ages. 43% of men were White, 8.6% Black, 4% Asian, 0.9% Hispanic, and 43.6% other or unknown. Median BMI was 26.8. Some of the men took medication on a regular basis that have been linked to ED including anti-hypertensives, antihistamines, and H2-receptor antagonists. The average total testosterone level was 368 ± 160 ng/dL. 10.6% of men had hypogonadism and 8.5% of men had hyperprolactinemia. Abnormalities of LH and FSH were noted in 10% and 9.1% of men, respectively. Regarding their ED treatment, 68.7% of men were given a phosphodiesterase type 5 inhibitor (PDE5i) and 2.4% were given alprostadil. Lastly, 12.9% of men were started on testosterone therapy.
The majority of men under age 40 with ED exhibit a normal hormonal milieu. Additionally, many men were using medications that have been linked to ED. Most men with ED were treated with a PDE5i.
Presented By: Daniel J. Mazur, Chicago, IL
Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA